Using machine learning to identify undiagnosable cancers

by Bendta Schroeder,Massachusetts Institute of Technology“Machine learning tools like this one could empower oncologists to choose more effective treatments and give more guidance to their patie

Updated on: January 04,2024 9

Using machine learning to identify undiagnosable cancers

by Bendta Schroeder,Massachusetts Institute of Technology“Machine learning tools like this one could empower oncologists to choose more effective treatments and give more guidance to their patie

Updated on:January 04,2024 9

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on: December 20,2023 11

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on:December 20,2023 11

Early clinical trial results show 'dramatic and rapid' regression of glioblastoma after next generation CAR-T therapy

by Mass General BrighamCredit: Unsplash/CC0 Public DomainA collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results amo

Updated on: March 20,2024 13

Early clinical trial results show 'dramatic and rapid' regression of glioblastoma after next generation CAR-T therapy

by Mass General BrighamCredit: Unsplash/CC0 Public DomainA collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results amo

Updated on:March 20,2024 13

New near-infrared activated photo-oxidants kill cancer cells without oxygen

A research team led by scientists from City University of Hong Kong (CityU) has achieved a significant breakthrough by inventing a new class of near-infrared-activated photo-oxidants that can effectiv

Updated on: November 12,2023 21

New near-infrared activated photo-oxidants kill cancer cells without oxygen

A research team led by scientists from City University of Hong Kong (CityU) has achieved a significant breakthrough by inventing a new class of near-infrared-activated photo-oxidants that can effectiv

Updated on:November 12,2023 21

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

byUniversity of Texas M. D. Anderson Cancer CenterBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaResearchers from The University of Texas MD

Updated on: December 19,2023 12

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

byUniversity of Texas M. D. Anderson Cancer CenterBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaResearchers from The University of Texas MD

Updated on:December 19,2023 12

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on: October 15,2023 27

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22, 2023Brittany LovelyFor patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-r

Updated on:October 15,2023 27

New research discovers gene mutations linked to prostate cancer

A study led by scientists from the Center for Genetic Epidemiology at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center has made a significant leap in our understanding of

Updated on: October 31,2023 27

New research discovers gene mutations linked to prostate cancer

A study led by scientists from the Center for Genetic Epidemiology at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center has made a significant leap in our understanding of

Updated on:October 31,2023 27

What Is Bloom Syndrome?

What Is Bloom Syndrome?ByCristina MutchlerPublished on August 16, 2021Medically reviewed byLyndsey Garbi, MDBloom syndrome, or Bloom's syndrome, is an extremely rareg

Updated on: March 17,2024 0

What Is Bloom Syndrome?

What Is Bloom Syndrome?ByCristina MutchlerPublished on August 16, 2021Medically reviewed byLyndsey Garbi, MDBloom syndrome, or Bloom's syndrome, is an extremely rareg

Updated on:March 17,2024 0

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

Updated on: October 15,2023 168

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

Updated on:October 15,2023 168

AI tool reveals cardiac risk for patients undergoing cancer therapy

byYale School of MedicineBaseline AI-ECG screening for LVSD and all-cause mortality risk. Adjusted cumulative hazard curves for all-cause mortality stratified by the AI-ECG LVSD probability. Cre

Updated on: September 27,2024 0

AI tool reveals cardiac risk for patients undergoing cancer therapy

byYale School of MedicineBaseline AI-ECG screening for LVSD and all-cause mortality risk. Adjusted cumulative hazard curves for all-cause mortality stratified by the AI-ECG LVSD probability. Cre

Updated on:September 27,2024 0

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate

Updated on: October 24,2023 270

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate

Updated on:October 24,2023 270

Report: Cancer deaths continue downward trend, modest improvements in survival for pancreatic cancer

byNational Cancer InstituteAge-standardized, delay-adjusted overall cancer incidence rates (2014–2018) and age-standardized overall cancer death rates (2015–2019) are illustrated for all cancer

Updated on: December 19,2023 12

Report: Cancer deaths continue downward trend, modest improvements in survival for pancreatic cancer

byNational Cancer InstituteAge-standardized, delay-adjusted overall cancer incidence rates (2014–2018) and age-standardized overall cancer death rates (2015–2019) are illustrated for all cancer

Updated on:December 19,2023 12